Iparomlimab
TNBC, Triple Negative Breast Cancer
Jiangsu Cancer Institute & HospitalPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the TNBC, Triple Negative Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Theprubicin Xijing Hospital | Phase 2 | B |
Fluzoparib Tianjin Medical University Cancer Institute and Hospital | Phase 2 | CCC |
177lu-betabart Radiopharm Theranostics, Ltd | Phase 1/2 | CC |
Omnipaque Alison Stopeck | Early Phase 1 | C |
177lu-rad204 Radiopharm Theranostics, Ltd | Early Phase 1 | C |
Same molecule, other indications
Iparomlimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →